In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

Singer Michael Trotter Jr of The War and Treaty, chef Franklin Becker of “Top Chef Masters,” and a beauty salon owner ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Novo Nordisk has benefited from favorable regulatory decisions, including the recent FDA approval of Ozempic for chronic kidney disease (CKD) patients with type 2 diabetes. This expanded ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial. The Danish ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

G LP-1 drugs containing semaglutide (the active ingredient in Ozempic and Wegovy) have exploded in popularity for their ...

An estimated 29 million Americans have diabetes, and the disease is the ... for other serious chronic conditions including hemophilia, growth disorders and obesity. With U.S. headquarters in ...

The impact of chronic kidney disease (CKD) keeps escalating around the world, and this burden is projected to rise with ...

Chronic Kidney Disease (CKD) indicates prolonged kidney damage over three months, often undetectable until significant harm occurs. Key risk factors include diabetes, high blood pressure ...